HRP20191461T1 - Novi 2' i/ili 5' derivati 3'-deoksi adenozina supstituirani aminokiselinskim esterom fosforamidata, kao antikancerogenog spoja - Google Patents

Novi 2' i/ili 5' derivati 3'-deoksi adenozina supstituirani aminokiselinskim esterom fosforamidata, kao antikancerogenog spoja Download PDF

Info

Publication number
HRP20191461T1
HRP20191461T1 HRP20191461T HRP20191461T1 HR P20191461 T1 HRP20191461 T1 HR P20191461T1 HR P20191461 T HRP20191461 T HR P20191461T HR P20191461 T1 HRP20191461 T1 HR P20191461T1
Authority
HR
Croatia
Prior art keywords
cancer
leukemia
compound
use according
lymphoma
Prior art date
Application number
Other languages
English (en)
Inventor
Hugh Griffith
Christopher Mcguigan
Valentina Ferrari
Michaela Serpi
Antunez Carmen Jimenez
Original Assignee
NuCana plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54771155&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20191461(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1421211.2A external-priority patent/GB201421211D0/en
Priority claimed from GBGB1519316.2A external-priority patent/GB201519316D0/en
Application filed by NuCana plc filed Critical NuCana plc
Publication of HRP20191461T1 publication Critical patent/HRP20191461T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/173Purine radicals with 2-deoxyribosyl as the saccharide radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/20Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/20Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Claims (14)

1. 3’-Deoksiadenozin-5’-O-[fenil(benziloksi-L-alaninil)] fosfat ili farmaceutski prihvatljiva sol, ester, sol estera ili solvat njegovog spoja.
2. 3’-Deoksiadenozin-5’-O-[fenil(benziloksi-L-alaninil)] fosfat u skladu s patentnim zahtjevom 1
3. Spoj u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2 za uporabu u vidu lijeka.
4. Spoj u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2 za uporabu u profilaksi ili liječenju raka.
5. Spoj za uporabu u skladu s patentnim zahtjevom 4 za uporabu u ciljanom djelovanju na matične stanice raka prilikom liječenja raka.
6. Spoj za uporabu u skladu s patentnim zahtjevom 5, naznačeno time što je rak izabran od leukemije, limfoma, raka dojke, raka pluća, raka debelog crijeva, raka prostate, raka jajnika, raka kože, raka mokraćnog mjehura, raka žučnih puteva i raka gušterače.
7. Spoj za uporabu u skladu s patentnim zahtjevom 5, naznačeno time što je rak izabran od raka dojke, raka CNS-a, raka debelog crijeva, Ewingovog sarkoma, melanoma, raka jetre, kolangiokarcinoma, raka jajnika, raka gušterače, raka pluća ne-malih stanica, raka mokraćnog mjehura, akutne mijeloidne leukemije, B-akutne limfoblastne leukemije, B-akutne limfoblastne leukemije, multiplog mijeloma i T-akutne limfoblastne leukemije.
8. Spoj za uporabu u skladu s patentnim zahtjevom 4, naznačeno time što je rak izabran iz grupe koja se sastoji od: leukemije, limfoma, multiplog mijeloma, raka pluća (uključujući rak pluća ne-malih stanica i sitnoćelijski rak pluća), raka jetre, raka dojke, raka mokraćnog mjehura, raka prostate, raka glave i vrata, neuroblastoma, sarkoma (uključujući Ewingov sarkom), tiroidnog karcinoma, raka kože (uključujući melanom), oralnog karcinoma skvamoznih stanica, raka mokraćnog mjehura, tumora Leydigovih stanica, raka žučnih puteva, kao što su kolangiokarcinom ili rak žučnog kanala, raka gušterače, raka debelog crijeva, kolorektalnog raka i ginekoloških karcinoma, uključujući rak jajnika, rak endometrija.
9. Spoj za uporabu u skladu s patentnim zahtjevom 8, naznačeno time što je rak leukemija ili limfom.
10. Spoj za uporabu u skladu s patentnim zahtjevom 9, naznačeno time što je leukemija izabrana iz grupe koja sadrži akutnu limfoblastnu leukemiju, akutnu mijelogenu leukemiju, akutnu promijelocitnu leukemiju, akutnu limfocitnu leukemiju, kroničnu mijelogenu leukemiju, kroničnu limfocitnu leukemiju, monoblastnu leukemiju, leukemiju vlasastih stanica, Hodgkinov limfom i ne-Hodgkinov limfom.
11. Spoj za uporabu u skladu s patentnim zahtjevom 10, naznačeno time što je leukemija akutna limfoblastna leukemija.
12. Spoj za uporabu u skladu s bilo kojim od patentnih zahtjeva 4 do 11, naznačeno time što je rak rekurentni ili nesenzitivni rak.
13. Spoj za uporabu u skladu s bilo kojim od patentnih zahtjeva 4 do 11, naznačeno time što je rak metastatski rak.
14. Farmaceutska kompozicija koja sadrži spoj u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2 u kombinaciji s farmaceutski prihvatljivim nosačem, razblaživačem ili ekscipijensom.
HRP20191461 2014-11-28 2019-08-13 Novi 2' i/ili 5' derivati 3'-deoksi adenozina supstituirani aminokiselinskim esterom fosforamidata, kao antikancerogenog spoja HRP20191461T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1421211.2A GB201421211D0 (en) 2014-11-28 2014-11-28 Chemical compounds
GBGB1519316.2A GB201519316D0 (en) 2015-11-02 2015-11-02 Chemical compounds
EP15804216.8A EP3224268B1 (en) 2014-11-28 2015-11-27 New 2' and/or 5' amino-acid ester phosphoramidate 3'-deoxy adenosine derivatives as anti-cancer compounds
PCT/GB2015/053628 WO2016083830A1 (en) 2014-11-28 2015-11-27 New 2' and/or 5' amino-acid ester phosphoramidate 3'-deoxy adenosine derivatives as anti-cancer compounds

Publications (1)

Publication Number Publication Date
HRP20191461T1 true HRP20191461T1 (hr) 2019-11-15

Family

ID=54771155

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20191461 HRP20191461T1 (hr) 2014-11-28 2019-08-13 Novi 2' i/ili 5' derivati 3'-deoksi adenozina supstituirani aminokiselinskim esterom fosforamidata, kao antikancerogenog spoja

Country Status (25)

Country Link
US (3) US10570168B2 (hr)
EP (2) EP3224268B1 (hr)
JP (2) JP6646668B2 (hr)
KR (2) KR20230098915A (hr)
CN (2) CN111909231A (hr)
AU (2) AU2015352203B2 (hr)
CA (1) CA2962373C (hr)
CL (1) CL2017001336A1 (hr)
CY (1) CY1122074T1 (hr)
DK (1) DK3224268T3 (hr)
EA (1) EA031727B1 (hr)
ES (1) ES2742167T3 (hr)
HR (1) HRP20191461T1 (hr)
HU (1) HUE046850T2 (hr)
IL (4) IL291927A (hr)
LT (1) LT3224268T (hr)
ME (1) ME03462B (hr)
MX (3) MX2017006942A (hr)
PH (1) PH12017500944A1 (hr)
PL (1) PL3224268T3 (hr)
PT (1) PT3224268T (hr)
RS (1) RS59264B1 (hr)
SG (2) SG10202009020VA (hr)
SI (1) SI3224268T1 (hr)
WO (1) WO2016083830A1 (hr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104974206B (zh) 2011-03-01 2019-08-23 努卡那生物医药有限责任公司 用于治疗癌症的5-氟-2’-脱氧尿苷的氨基磷酸酯衍生物
AU2015352203B2 (en) 2014-11-28 2019-08-15 NuCana plc New 2' and/or 5' amino-acid ester phosphoramidate 3'-deoxy adenosine derivatives as anti-cancer compounds
GB201522764D0 (en) * 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201609601D0 (en) 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
GB201709471D0 (en) * 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201720279D0 (en) 2017-12-05 2018-01-17 Nucana Biomed Ltd Anticancer compounds
CN110669088B (zh) * 2018-07-02 2023-03-28 成都阿奇生物医药科技有限公司 N-(2-乙基胺)苯磺酰胺基虫草素衍生物及其制备方法和应用
GB201904544D0 (en) 2019-04-01 2019-05-15 NuCana plc Anticancer compounds
CN111888373A (zh) * 2019-05-05 2020-11-06 上海医药集团股份有限公司 一种虫草素或其药学上可接受的盐的应用
WO2023218202A2 (en) 2022-05-12 2023-11-16 NuCana plc Cancer treatment
CN116768949A (zh) * 2022-07-12 2023-09-19 南京工业大学 一种基于3’-脱氧腺苷经化学修饰改性的具有抗癌效应的化合物

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4357324A (en) 1981-02-24 1982-11-02 The United States Of America As Represented By The Department Of Health And Human Services Prodrug derivatives of 9β-D-arabinofuranosyl-2-fluoroadenine
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
EP1827460A4 (en) * 2004-12-09 2012-03-14 Univ Minnesota NUCLEOSIDE WITH ANTIVIRAL AND ANTI-CANCER EFFECT
GB0505781D0 (en) * 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
WO2006121820A1 (en) * 2005-05-05 2006-11-16 Valeant Research & Development Phosphoramidate prodrugs for treatment of viral infection
GB0623493D0 (en) 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
PE20120013A1 (es) 2009-01-09 2012-02-02 Univ Cardiff Fosforamidato derivados de guanosina compuestos nucleosidos para tratamiento de infecciones virales
WO2010091386A2 (en) 2009-02-06 2010-08-12 Rfs Pharma, Llc Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections
KR20110128947A (ko) * 2009-03-20 2011-11-30 앨리오스 바이오파마 인크. 치환된 뉴클레오시드 및 뉴클레오티드 유사체
BR112013001267A2 (pt) 2010-07-19 2016-05-17 Gilead Sciences Inc métodos para a preparação de pró-fármacos de fosforamidato diasteromericamente puro
WO2012040126A1 (en) * 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
PE20140608A1 (es) 2010-09-22 2014-06-12 Alios Biopharma Inc Analogos de nucleotidos sustituidos
GB201016855D0 (en) 2010-10-06 2010-11-17 Nucana Biomed Ltd Chemical compounds
CN104974206B (zh) 2011-03-01 2019-08-23 努卡那生物医药有限责任公司 用于治疗癌症的5-氟-2’-脱氧尿苷的氨基磷酸酯衍生物
WO2013070887A1 (en) * 2011-11-10 2013-05-16 Inhibitex, Inc. Substituted purine nucleosides, phosphoramidate and phosphordiamidate derivatives for treatment of viral infections
EP3043803B1 (en) 2013-09-11 2022-04-27 Emory University Nucleotide and nucleoside compositions and their uses
US10030044B2 (en) 2013-11-27 2018-07-24 Idenix Pharmaceuticals Llc Nucleotides for the treatment of liver cancer
MX2020004054A (es) 2014-06-25 2021-11-30 NuCana plc Formulacion que comprende un profarmaco de gemcitabina.
CN105646629A (zh) 2014-11-25 2016-06-08 广州市恒诺康医药科技有限公司 L-核苷类化合物及其应用
AU2015352203B2 (en) * 2014-11-28 2019-08-15 NuCana plc New 2' and/or 5' amino-acid ester phosphoramidate 3'-deoxy adenosine derivatives as anti-cancer compounds
WO2016145142A1 (en) 2015-03-10 2016-09-15 Emory University Nucleotide and nucleoside therapeutics compositions and uses related thereto
BR112017024461B1 (pt) 2015-05-14 2023-04-04 NuCana plc Usos de nuc-1031 para o tratamento de câncer
GB201522764D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201609601D0 (en) 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201609602D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Chemical compounds
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives

Also Published As

Publication number Publication date
JP2020075928A (ja) 2020-05-21
PL3224268T3 (pl) 2019-11-29
KR102548806B1 (ko) 2023-06-27
CA2962373C (en) 2023-04-25
CN107207554B (zh) 2020-09-11
IL251353A0 (en) 2017-05-29
EA031727B1 (ru) 2019-02-28
DK3224268T3 (da) 2019-09-02
PT3224268T (pt) 2019-09-04
CY1122074T1 (el) 2020-11-25
PH12017500944A1 (en) 2017-11-20
MX2020010375A (es) 2022-07-19
WO2016083830A1 (en) 2016-06-02
US20220306675A1 (en) 2022-09-29
NZ767066A (en) 2022-03-25
EP3224268B1 (en) 2019-06-26
JP6978524B2 (ja) 2021-12-08
US20170253629A1 (en) 2017-09-07
AU2019232929B2 (en) 2020-09-10
CL2017001336A1 (es) 2017-12-15
MX2022008744A (es) 2022-07-27
AU2015352203B2 (en) 2019-08-15
ES2742167T3 (es) 2020-02-13
IL291927A (en) 2022-06-01
LT3224268T (lt) 2019-09-25
EP3224268A1 (en) 2017-10-04
US20200181189A1 (en) 2020-06-11
IL251353B (en) 2020-08-31
JP2017535587A (ja) 2017-11-30
IL276109A (en) 2020-08-31
MX2017006942A (es) 2017-08-24
BR112017011187A2 (pt) 2018-01-02
KR20170087465A (ko) 2017-07-28
HUE046850T2 (hu) 2020-03-30
CN107207554A (zh) 2017-09-26
US11352387B2 (en) 2022-06-07
SI3224268T1 (sl) 2019-10-30
AU2019232929A1 (en) 2019-10-10
SG10202009020VA (en) 2020-10-29
NZ730919A (en) 2021-02-26
AU2015352203A1 (en) 2017-04-27
EP3683225A1 (en) 2020-07-22
CA2962373A1 (en) 2016-06-02
SG11201702369UA (en) 2017-04-27
IL292062B2 (en) 2023-06-01
ME03462B (me) 2020-01-20
JP6646668B2 (ja) 2020-02-14
EA201791182A1 (ru) 2017-09-29
KR20230098915A (ko) 2023-07-04
CN111909231A (zh) 2020-11-10
RS59264B1 (sr) 2019-10-31
US10570168B2 (en) 2020-02-25
IL292062A (en) 2022-06-01
IL276109B (en) 2022-05-01

Similar Documents

Publication Publication Date Title
HRP20191461T1 (hr) Novi 2' i/ili 5' derivati 3'-deoksi adenozina supstituirani aminokiselinskim esterom fosforamidata, kao antikancerogenog spoja
HRP20201264T1 (hr) Prolijekovi gemcitabina
HRP20202073T1 (hr) Derivati n-(fenilsulfonil)benzamida kao bcl-2 inhibitori
HRP20150952T1 (hr) Određeni triazolopirazini, njihovi pripravci i postupci njihove upotrebe
HRP20230400T1 (hr) Benzilamino supstituirani piridopirimidinoni i derivati kao inhibitori sos1
HRP20210212T1 (hr) Triciklični spoj kao antikancerogeni agensi
MY198880A (en) Phosphoramidate nucleoside derivatives as anticancer agents
HRP20180158T1 (hr) Spojevi biarilamida kao inhibitori kinaze
MX2023008994A (es) Derivados de pirazina fusionados como inhibidores de a2a/a2b.
MX2016006919A (es) Nucleotidos para el tratamiento de cancer de higado.
DOP2011000367A (es) DERIVADOS DE SULFONAMIDA SUSTITUIDA CON 1H-PIRROLO[2,3,b]PIRIDIN-5-ILOXI COMO AGENTES INDUCTORES DE APOPTOSIS PARA EL TRATAMIENTO DE CANCER Y ENFERMEDADES INMUNES Y AUTOINMUNES
BR112017020336A2 (pt) análogos de nucleosídeos 5?-substituídos
WO2017091837A3 (en) Therapeutic agents containing cannabis flavonoid derivatives targeting kinases, sirtuins and oncogenic agents for the treatment of cancers
MX371034B (es) Derivados de amidas policíclicas como inhibidores de cdk9.
MX2020012376A (es) Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b.
BR112015023705A2 (pt) composto da fórmula (ia) ou um sal, hidrato, solvato ou forma cristalina farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composto e método para síntese do composto da fórmula (ia)
SA515370134B1 (ar) تركيبة صيدلانية تحتوي على عامل علاجي قائم على الهيموغلوبين المعدل لعلاج السرطان المستهدف والتصوير التشخيصي
MD4643C1 (ro) Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin
MX2019010875A (es) Derivados de uncialamicina, metodos de sintesis y su uso como agentes antitumor.
JP2019521971A5 (hr)
NZ726365A (en) Combinations for treating cancers
HRP20201681T1 (hr) Inhibitor aurora a kinaze
AU2015217450A8 (en) Pyrazolone compounds and uses thereof
PH12018501292A1 (en) Pharmaceutical compositions comprising phenylaminopyridine derviative
WO2018054989A9 (en) Benzoimidazole derivatives as anticancer agents